title: Proceedings of the 2013 CINP summit: innovative partnerships to accelerate CNS drug discovery for improved patient care.
abstract: Central nervous system (CNS) diseases and, in particular, mental health disorders, are becoming recognized as the health challenge of the 21(st) century. Currently, at least 10% of the global population is affected by a mental health disorder, a figure that is set to increase year on year. Meanwhile, the rate of development of new CNS drugs has not increased for many years, despite unprecedented levels of investment. In response to this state of affairs, the Collegium Internationale Neuro-Psychopharmacologicum (CINP) convened a summit to discuss ways to reverse this disturbing trend through new partnerships to accelerate CNS drug discovery. The objectives of the Summit were to explore the issues affecting the value chain (i.e. the chain of activities or stakeholders that a company engages in/with to deliver a product to market) in brain research, thereby gaining insights from key stakeholders and developing actions to address unmet needs; to identify achievable objectives to address the issues; to develop action plans to bring about measurable improvements across the value chain and accelerate CNS drug discovery; and finally, to communicate recommendations to governments, the research and development community, and other relevant stakeholders. Summit outputs include the following action plans, aligned to the pressure points within the brain research-drug development value chain: Code of conduct dealing with conflict of interest issues, Prevention, early diagnosis, and treatment, Linking science and regulation, Patient involvement in trial design, definition of endpoints, etc., Novel trial design, Reproduction and confirmation of data, Update of intellectual property (IP) laws to facilitate repurposing and combination therapy (low priority), Large-scale, global patient registries, Editorials on nomenclature, biomarkers, and diagnostic tools, and Public awareness, with brain disease advocates to attend G8 meetings and World Economic Forum (WEF) Annual meetings in Davos, Switzerland. In this context Professor Barbara Sahakian recently made a formal presentation at the World Economic Forum (see Barbara Sahakian Blog from April 11, 2014, at https://forumblog.org/people/barbara-sahakian/) Full details of the discussions that formed the bases for these actions are presented in the main body of this document.
authors.affiliation: Collegium Internationale Neuro-Psychopharmacologicum, Vancouver, British Columbia, Canada (Dr Phillips); Innovation Fund Denmark, Copenhagen, Denmark (Dr Hongaard-Andersen); US Food and Drug Administration, Silver Spring, Maryland, USA (Dr Moscicki); University of Cambridge, Cambridge, UK (Dr Sahakian); McGill University, Montreal, Quebec, Canada (Dr Quirion); Duke NUS, Singapore (Dr Krishnan); Deutsche Bank, London, UK (Mr Race) aphillips@psych.ubc.ca.
authors.forename: Anthony George
authors.initials: AG
authors.lastname: Phillips
authors.affiliation: Collegium Internationale Neuro-Psychopharmacologicum, Vancouver, British Columbia, Canada (Dr Phillips); Innovation Fund Denmark, Copenhagen, Denmark (Dr Hongaard-Andersen); US Food and Drug Administration, Silver Spring, Maryland, USA (Dr Moscicki); University of Cambridge, Cambridge, UK (Dr Sahakian); McGill University, Montreal, Quebec, Canada (Dr Quirion); Duke NUS, Singapore (Dr Krishnan); Deutsche Bank, London, UK (Mr Race).
authors.forename: Peter
authors.initials: P
authors.lastname: Hongaard-Andersen
authors.affiliation: Collegium Internationale Neuro-Psychopharmacologicum, Vancouver, British Columbia, Canada (Dr Phillips); Innovation Fund Denmark, Copenhagen, Denmark (Dr Hongaard-Andersen); US Food and Drug Administration, Silver Spring, Maryland, USA (Dr Moscicki); University of Cambridge, Cambridge, UK (Dr Sahakian); McGill University, Montreal, Quebec, Canada (Dr Quirion); Duke NUS, Singapore (Dr Krishnan); Deutsche Bank, London, UK (Mr Race).
authors.forename: Richard A
authors.initials: RA
authors.lastname: Moscicki
authors.affiliation: Collegium Internationale Neuro-Psychopharmacologicum, Vancouver, British Columbia, Canada (Dr Phillips); Innovation Fund Denmark, Copenhagen, Denmark (Dr Hongaard-Andersen); US Food and Drug Administration, Silver Spring, Maryland, USA (Dr Moscicki); University of Cambridge, Cambridge, UK (Dr Sahakian); McGill University, Montreal, Quebec, Canada (Dr Quirion); Duke NUS, Singapore (Dr Krishnan); Deutsche Bank, London, UK (Mr Race).
authors.forename: Barbara
authors.initials: B
authors.lastname: Sahakian
authors.affiliation: Collegium Internationale Neuro-Psychopharmacologicum, Vancouver, British Columbia, Canada (Dr Phillips); Innovation Fund Denmark, Copenhagen, Denmark (Dr Hongaard-Andersen); US Food and Drug Administration, Silver Spring, Maryland, USA (Dr Moscicki); University of Cambridge, Cambridge, UK (Dr Sahakian); McGill University, Montreal, Quebec, Canada (Dr Quirion); Duke NUS, Singapore (Dr Krishnan); Deutsche Bank, London, UK (Mr Race).
authors.forename: Rémi
authors.initials: R
authors.lastname: Quirion
authors.affiliation: Collegium Internationale Neuro-Psychopharmacologicum, Vancouver, British Columbia, Canada (Dr Phillips); Innovation Fund Denmark, Copenhagen, Denmark (Dr Hongaard-Andersen); US Food and Drug Administration, Silver Spring, Maryland, USA (Dr Moscicki); University of Cambridge, Cambridge, UK (Dr Sahakian); McGill University, Montreal, Quebec, Canada (Dr Quirion); Duke NUS, Singapore (Dr Krishnan); Deutsche Bank, London, UK (Mr Race).
authors.forename: K Ranga Rama
authors.initials: KR
authors.lastname: Krishnan
authors.affiliation: Collegium Internationale Neuro-Psychopharmacologicum, Vancouver, British Columbia, Canada (Dr Phillips); Innovation Fund Denmark, Copenhagen, Denmark (Dr Hongaard-Andersen); US Food and Drug Administration, Silver Spring, Maryland, USA (Dr Moscicki); University of Cambridge, Cambridge, UK (Dr Sahakian); McGill University, Montreal, Quebec, Canada (Dr Quirion); Duke NUS, Singapore (Dr Krishnan); Deutsche Bank, London, UK (Mr Race).
authors.forename: Tim
authors.initials: T
authors.lastname: Race
mesh_terms: D000818:Animals; D035843:Biomedical Research; D002491:Central Nervous System Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D055808:Drug Discovery; D006801:Humans; D005791:Patient Care; D055818:Public-Private Sector Partnerships
chemical_list: D002491:Central Nervous System Agents
keywords: CNS drug pipeline; brain health; clinical neuropsychopharmacology; public-private partnerships; science policy